Prestigious international publication

   Our latest paper has been published in the prestigious Journal of Cerebral Blood Flow and Metabolism (JCBFM) under the title "Trifluoperazine reduces infarct size, restores neurovascular coupling, and improves early outcomes in experimental acute ischemic stroke." The study demonstrates that a well-established drug, originally developed for the treatment of psychiatric disorders, may reduce brain damage caused by stroke and improve recovery. Under experimental conditions, the drug reduces cerebral edema, protects nerve cells, and helps restore adequate blood supply to the brain. Because trifluoperazine is already an approved medication, these findings may provide the basis for drug repurposing for potential treatment for acute ischemic stroke. Congratulations to the authors on their high-quality research!